首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
Authors:J.‐F. Yale  G. Bakris  B. Cariou  J. Nieto  E. David‐Neto  D. Yue  E. Wajs  K. Figueroa  J. Jiang  G. Law  K. Usiskin  G. Meininger
Affiliation:1. Department of Medicine, Royal Victoria Hospital and McGill University, , Montreal, Canada;2. Department of Medicine, The University of Chicago Medicine, , Chicago, IL, USA;3. Department of Endocrinology & Center of Clinical Investigation, Nantes University Hospital, , Nantes, France;4. Servicio de Nefrologia y Riesgo Vascular, Hospital General Universitario, , Ciudad Real, Spain;5. Núcleo Avan?ado de Nefrologia, Hospital Sírio‐Libanês, , S?o Paulo, Brazil;6. Diabetes Centre, Royal Prince Alfred Hospital, University of Sydney, , Camperdown, Australia;7. Janssen Research & Development, , Beerse, Belgium;8. Janssen Research & Development, LLC, , Raritan, NJ, USA
Abstract:
Keywords:diabetic nephropathy  randomized trial  sodium glucose co‐transporter 2 (SGLT2) inhibitor  type 2 diabetes mellitus
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号